| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
95%
|
USAspending awards from Department of Veterans Affairs: $29,064,047 across 5 awards. 36C24E25N0228 WHOLE GENOME SEQUENCING; 36C24E24N0268 WHOLE GENOME SEQUENCING; 36C24E23N0192 WHOLE GENOME SEQUENCIN… |
| MERCK-CO-INC |
MERCK-CO-INC |
92%
|
We also derive a significant portion of our revenue from Merck, which accounted for 19% and 7% of our revenue for the three months ended March 31, 2026 and each of the years ended December 31, 2025 a… |
| MODERNA |
MODERNA |
92%
|
We also derive a significant portion of our revenue from Moderna, which accounted for 28% and 5% of our revenue for the years ended December 31, 2024 and 2023, respectively. |
| NATERA |
NATERA |
92%
|
We currently derive a significant portion of our revenue from Natera, which accounted for 30% and 43% of our revenue for the years ended December 31, 2024 and 2023, respectively. |
| VA-MVP |
VA-MVP |
92%
|
We derive a significant portion of our revenue from the VA MVP, which accounted for 16% of our revenue for the three months ended March 31, 2026, and 17% and 9% of our revenue for the years ended Dec… |
| MRK |
Merck & Co., Inc. |
85%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from PSNL graph: he sale of its equity securities and cash from operations. million was reclassified from accumulated other comprehensi… |
| MRK |
Merck & Co., Inc. |
85%
|
he sale of its equity securities and cash from operations. million was reclassified from accumulated other comprehensive loss to net loss within Other income (expense), net. 75 Table of Contents % % … |
| NATERA-NEOGENOMICS-INC-PREDICINE-INC |
NATERA-NEOGENOMICS-INC-PREDICINE-INC |
85%
|
s Incorporated in June 2023, Laboratory Corporation of America Holdings, MedGenome Inc., Myriad Genetics, Inc., Natera, NeoGenomics, Inc., Predicine, Inc., SAGA Diagnostics AB which is expected to be… |
| ROCHE-MOLECULAR-SYSTEMS-INC |
ROCHE-MOLECULAR-SYSTEMS-INC |
85%
|
ogy therapies approved by the FDA along with companion diagnostics increases. For example, the FDA has approved several such targeted oncology therapies that use companion diagnostics, including the … |
| TEM |
Tempus AI, Inc. |
85%
|
Reciprocal relationship from TEM graph: Reciprocal relationship from PSNL graph: requirements, and our needs for additional financing and our ability to obtain financing when needed; • future reimbur… |
| TEM |
Tempus AI, Inc. |
85%
|
requirements, and our needs for additional financing and our ability to obtain financing when needed; • future reimbursement and reimbursement rulings and the timing thereof; • our business strategie… |
| FLGT |
Fulgent Genetics, Inc. |
72%
|
t or potential competitors, including Adela, Inc., BostonGene Corporation, Caris Life Sciences, Inc., DELFI Diagnostics, Inc., Exact Sciences Corporation, Foresight Diagnostics Inc. (“Foresight”), Fo… |
| FLGT |
Fulgent Genetics, Inc. |
72%
|
Reciprocal relationship from FLGT graph: Reciprocal relationship from PSNL graph: t or potential competitors, including Adela, Inc., BostonGene Corporation, Caris Life Sciences, Inc., DELFI Diagnosti… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
venue and accounts receivable; in particular, we currently derive a substantial portion of our revenue from two of our largest customers, Moderna and the VA MVP, and in the past have derived a substa… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from PSNL graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from PSNL graph: Reciprocal relationship from MYGN g… |
| ADELA-INC-BOSTONGENE-CORPORATION-CARIS-LIFE-SCIE |
ADELA-INC-BOSTONGENE-CORPORATION-CARIS-LIFE-SCIE |
62%
|
sidered superior to those of our competitors; • any negative publicity regarding our or our competitors’ services resulting from defects or errors; • our success obtaining and maintaining patent and … |
| DELFI-DIAGNOSTICS-INC-EXACT-SCIENCES-CORPORATION |
DELFI-DIAGNOSTICS-INC-EXACT-SCIENCES-CORPORATION |
62%
|
sidered superior to those of our competitors; • any negative publicity regarding our or our competitors’ services resulting from defects or errors; • our success obtaining and maintaining patent and … |
| FORESIGHT-DIAGNOSTICS-INC |
FORESIGHT-DIAGNOSTICS-INC |
62%
|
▪ NeXT Personal had an average lead time for detecting cancer progression of 81 days over imaging. • Highlighted clinical performance of NeXT Personal at the European Society of Medical Oncology (ESM… |
| HAYSTACK-ONCOLOGY-INC |
HAYSTACK-ONCOLOGY-INC |
62%
|
eeq Technology Inc., GRAIL, Inc., Guardant Health, Inc., Haystack Oncology, Inc., which was acquired by Quest Diagnostics Incorporated in June 2023, Laboratory Corporation of America Holdings, MedGen… |
| INC-ROCHE-MOLECULAR-SYSTEMS-INC |
INC-ROCHE-MOLECULAR-SYSTEMS-INC |
62%
|
cine, Inc., Roche Molecular Systems, Inc., SAGA Diagnostics AB, Tempus, and Veracyte, Inc. may have more widespread brand recognition or substantially greater financial or technical resources, develo… |
| NATERA-NEOGENOMICS-INC-NOVOGENE-CORPORATION-PRED |
NATERA-NEOGENOMICS-INC-NOVOGENE-CORPORATION-PRED |
62%
|
uired by Quest Diagnostics Incorporated in June 2023, Laboratory Corporation of America Holdings, MedGenome Inc., Myriad Genetics, Inc., Natera, NeoGenomics, Inc., Novogene Corporation, Predicine, In… |
| TECHNOLOGY-INC-GRAIL-INC-GUARDANT-HEALTH-INC |
TECHNOLOGY-INC-GRAIL-INC-GUARDANT-HEALTH-INC |
62%
|
eeq Technology Inc., GRAIL, Inc., Guardant Health, Inc., Haystack Oncology, Inc., which was acquired by Quest Diagnostics Incorporated in June 2023, Laboratory Corporation of America Holdings, MedGen… |
| VETERANS-AFFAIRS-MILLION-VETERAN-PROGRAM-NATERA- |
VETERANS-AFFAIRS-MILLION-VETERAN-PROGRAM-NATERA- |
62%
|
d other resources, cost savings, capital requirements, and our needs for additional financing and our ability to obtain financing when needed; • future reimbursement and reimbursement rulings; • our … |
